[An experimental study of the antitumor properties of olipifat].
Olipiphat is an original lignin-based mix developed by special technology. It showed antitumor action against carcinoma of Ehrlich, breast adenocarcinoma Ca 755, melanoma B 16, lung carcinoma of Lewis, lymphosarcoma of Pliss, Walker's carcinoma, sarcoma 45 (tumor growth inhibition by 83-92%, increase in survival by 42-54%) and spontaneous murine tumors (the total of 9 pathologies). The drug was administered by 3-5 injections at 2-3 day intervals. No immediate cytotoxic or cytostatic effects were registered.
Filov
V A
VA
N. N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Reztsova
V V
VV
Kil'maeva
N E
NE
Petukhov
D V
DV
Pinchuk
B T
BT
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001580:Benzopyrenes; D002294:Carcinoma, Squamous Cell; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008031:Lignin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D051379:Mice; D008815:Mice, Inbred Strains; D009062:Mouth Neoplasms; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D051381:Rats; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects; D001749:Urinary Bladder Neoplasms
D000970:Antineoplastic Agents; D001580:Benzopyrenes; C413426:olipifat; D008031:Lignin